You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020160028
Dec 20202508
Jan 202163016
Feb 202156011
Mar 202182017
Apr 202165014
May 202113015
Jun 20210018
Jul 20211019
Aug 20210022
Sep 20210015
Oct 202122028
Nov 202128019
Dec 20213603
Jan 202230012
Feb 20221206
Mar 20224208
Apr 202290020
May 202256010
Jun 20223309
Jul 20225208
Aug 20225107
Sep 202249014
Oct 20225809
Nov 202258013
Dec 20222605
Jan 20236807
Feb 20238008
Mar 202348010
Apr 202312209
May 20234805
Jun 2023138018
Jul 20238208
Aug 20236002
Sep 20237009
Oct 20235808
Nov 202356012
Dec 20236605
Jan 20244203
Feb 20242603
Mar 20244409
Apr 20244005
May 20243407
Jun 20244003
Jul 202480011
Aug 20243602
Sep 20243605
Oct 202436013
Nov 20245606
Dec 202434015
Jan 202554016
Feb 20251204
Mar 20250013
Apr 2025009
May 2025006
Jun 2025003
Total25740588